<DOC>
	<DOC>NCT02436135</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of idelalisib in adults receiving ruxolitinib as therapy for intermediate to high risk primary myelofibrosis (PMF), post-polycythemia vera, or post-essential thrombocythemia myelofibrosis (post-PV MF or post-ET MF) with progressive or relapsed disease.</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia, Essential</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Key Individuals must have been on a stable dose of ruxolitinib for at least 4 weeks prior to study entry Individuals with PMF, postPV MF, or postET MF classified as high risk or intermediate risk as defined by the Dynamic International Prognostic Scoring System (DIPSS) for PMF or DIPSS Plus, if cytogenetics are available Individuals with PMF, postPV MF, or postET MF who are receiving ruxolitinib and meet 2013 Revised International Working Group for Myelofibrosis Research and Treatment (IWGMRT) and European Leukemia Net (ELN) response criteria with progressive and relapsed disease, with modifications for progressive disease complete remission (CR), partial remission (PR), or clinical improvement (CI) European Cooperative Oncology Group (ECOG) performance status of â‰¤ 2 Required screening laboratory values as described in the protocol Willing and able to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions including mandatory prophylaxis for pneumocystis jiroveci pneumonia (PJP) Able to understand and willing to sign the informed consent form Key Individuals on a stable ruxolitinib dose of 5 mg once daily History of prior allogeneic bone marrow progenitor cell or solid organ transplantation Ongoing druginduced liver injury, alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver Ongoing druginduced pneumonitis Ongoing inflammatory bowel disease Ongoing alcohol or drug addiction Symptomatic congestive heart failure (New York Heart Association Classification &gt; Class II), unstable angina, or unstable cardiac arrhythmia requiring medication Known hypersensitivity to the study investigational medicinal product (IMP), the metabolites, or formulation excipients Unwilling or unable to take oral medication Unresolved nonhematologic toxicities from prior therapies that are &gt; Common terminology Criteria for Adverse Events (CTCAE) Grade 1 (with the exception of alopecia [Grade 1 or 2 permitted]) Pregnant or lactating females Cytomegalovirus (CMV): Ongoing infection, treatment, or prophylaxis within the past 28 days NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>